File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prevention and management of drug resistance for antihepatitis B treatment

TitlePrevention and management of drug resistance for antihepatitis B treatment
Authors
Issue Date2009
PublisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/j.lancetid
Citation
The Lancet Infectious Diseases, 2009, v. 9 n. 4, p. 256-264 How to Cite?
AbstractEmergence of drug resistance in antiviral therapy for chronic hepatitis B negates treatment benefits. There is a lower chance for emergence of resistance for drugs with rapid and potent viral suppression and a high genetic barrier for resistant mutations. Measurement of viral load at 24 weeks' treatment to aid decision making is mandatory for patients receiving drugs that are associated with a higher resistance rate. Combination treatment with drugs that belong to different groups is associated with a lower chance of resistance. To ensure better control of viral replication in patients with drug resistance, the addition of another drug without an overlapping resistance profile should be given as early as possible, preferably at the time when genotypic resistance emerges. With such strategies, most patients can be maintained in clinical remission. However, because of the mechanism of viral persistence, research efforts should continue to anticipate and prevent the emergence of multidrug-resistant strains. © 2009 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/163236
ISSN
2015 Impact Factor: 21.372
2015 SCImago Journal Rankings: 11.233
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_US
dc.contributor.authorFung, Jen_US
dc.contributor.authorWong, DKHen_US
dc.contributor.authorLai, CLen_US
dc.date.accessioned2012-09-05T05:29:02Z-
dc.date.available2012-09-05T05:29:02Z-
dc.date.issued2009en_US
dc.identifier.citationThe Lancet Infectious Diseases, 2009, v. 9 n. 4, p. 256-264en_US
dc.identifier.issn1473-3099en_US
dc.identifier.urihttp://hdl.handle.net/10722/163236-
dc.description.abstractEmergence of drug resistance in antiviral therapy for chronic hepatitis B negates treatment benefits. There is a lower chance for emergence of resistance for drugs with rapid and potent viral suppression and a high genetic barrier for resistant mutations. Measurement of viral load at 24 weeks' treatment to aid decision making is mandatory for patients receiving drugs that are associated with a higher resistance rate. Combination treatment with drugs that belong to different groups is associated with a lower chance of resistance. To ensure better control of viral replication in patients with drug resistance, the addition of another drug without an overlapping resistance profile should be given as early as possible, preferably at the time when genotypic resistance emerges. With such strategies, most patients can be maintained in clinical remission. However, because of the mechanism of viral persistence, research efforts should continue to anticipate and prevent the emergence of multidrug-resistant strains. © 2009 Elsevier Ltd. All rights reserved.en_US
dc.languageengen_US
dc.publisherThe Lancet Publishing Group. The Journal's web site is located at http://www.elsevier.com/locate/j.lancetiden_US
dc.relation.ispartofThe Lancet Infectious Diseasesen_US
dc.subject.meshAntiviral Agents - Pharmacology - Therapeutic Useen_US
dc.subject.meshDrug Resistance, Viral - Geneticsen_US
dc.subject.meshHepatitis B Virus - Drug Effects - Geneticsen_US
dc.subject.meshHepatitis B, Chronic - Drug Therapy - Virologyen_US
dc.subject.meshHumansen_US
dc.subject.meshMutationen_US
dc.subject.meshViral Loaden_US
dc.titlePrevention and management of drug resistance for antihepatitis B treatmenten_US
dc.typeArticleen_US
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_US
dc.identifier.emailFung, J:jfung@sicklehut.comen_US
dc.identifier.emailWong, DKH:danywong@hku.hken_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityYuen, MF=rp00479en_US
dc.identifier.authorityFung, J=rp00518en_US
dc.identifier.authorityWong, DKH=rp00492en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S1473-3099(09)70056-8en_US
dc.identifier.pmid19324298-
dc.identifier.scopuseid_2-s2.0-62549089691en_US
dc.identifier.hkuros161051-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-62549089691&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume9en_US
dc.identifier.issue4en_US
dc.identifier.spage256en_US
dc.identifier.epage264en_US
dc.identifier.eissn1474-4457-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridYuen, MF=7102031955en_US
dc.identifier.scopusauthoridFung, J=23091109300en_US
dc.identifier.scopusauthoridWong, DKH=7401535819en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats